FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315750281> ?p ?o ?g. }

• W4315750281 abstract "Abstract Cepharanthine (CEP) is a natural remedy that potently inhibits SARS-CoV-2 activity both in vitro and in vivo. We conducted a proof-of-concept, double-blind, randomized, placebo-controlled trial among adults with asymptomatic or mild coronavirus disease 2019 (COVID-19). Patients were stratified randomly to de novo infection or viral rebound, and assigned in a 1:1:1 ratio to receive 60 mg/day or 120 mg/day of CEP or placebo. Primary outcome the time from randomization to negative nasopharyngeal swab, and safety were evaluated. A total of 262 de novo infected and 124 viral rebound patients underwent randomization. In the 188 de novo patients included in modified intention-to-treat (mITT) population, when compared with placebo, 60 mg/day CEP slightly shortened the time to negative (difference=-0.77 days, hazard ratio (HR)=1.40, 95% CI 0.97 to 2.01, p=0.072), and 120 mg/day CEP did not show the trend. Among de novo patients in the per-protocol set (PPS), 60 mg/day CEP significantly shortened the time to negative (difference=-0.87 days, HR=1.56, 95% CI 1.03 to 2.37, p=0.035). Among viral rebound patients in the mITT population, neither 120 mg/day nor 60 mg/day CEP significantly shortened the time to negative compared to placebo. Adverse events were not different among the three groups, and no serious adverse events occurred. Treatment of asymptomatic or mild Covid-19 with 120 mg/day or 60 mg/day CEP did not shorten the time to negative compared with placebo, without evident safety concerns. Among de novo infected patients with good compliance, 60 mg/day CEP significantly shortened the time to negative compared with placebo ( NCT05398705 )." @default.
• W4315750281 created "2023-01-13" @default.
• W4315750281 creator A5004380039 @default.
• W4315750281 creator A5004861529 @default.
• W4315750281 creator A5005314996 @default.
• W4315750281 creator A5006122583 @default.
• W4315750281 creator A5006651636 @default.
• W4315750281 creator A5007773312 @default.
• W4315750281 creator A5022679996 @default.
• W4315750281 creator A5024370074 @default.
• W4315750281 creator A5025856206 @default.
• W4315750281 creator A5032235768 @default.
• W4315750281 creator A5037654523 @default.
• W4315750281 creator A5040894984 @default.
• W4315750281 creator A5042241049 @default.
• W4315750281 creator A5042668842 @default.
• W4315750281 creator A5050943206 @default.
• W4315750281 creator A5053202977 @default.
• W4315750281 creator A5059475761 @default.
• W4315750281 creator A5059986506 @default.
• W4315750281 creator A5060957183 @default.
• W4315750281 creator A5069190300 @default.
• W4315750281 creator A5071524817 @default.
• W4315750281 creator A5075889094 @default.
• W4315750281 creator A5084715837 @default.
• W4315750281 creator A5086664284 @default.
• W4315750281 creator A5088680035 @default.
• W4315750281 date "2023-01-12" @default.
• W4315750281 modified "2023-09-28" @default.
• W4315750281 title "Safety and Efficacy of Oral administrated Cepharanthine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial" @default.
• W4315750281 cites W1974037945 @default.
• W4315750281 cites W2052395598 @default.
• W4315750281 cites W2094027050 @default.
• W4315750281 cites W2415990367 @default.
• W4315750281 cites W2944435500 @default.
• W4315750281 cites W3009456922 @default.
• W4315750281 cites W3009885589 @default.
• W4315750281 cites W3012415734 @default.
• W4315750281 cites W3012849736 @default.
• W4315750281 cites W3014067025 @default.
• W4315750281 cites W3020773974 @default.
• W4315750281 cites W3025232799 @default.
• W4315750281 cites W3026764413 @default.
• W4315750281 cites W3043959829 @default.
• W4315750281 cites W3044927477 @default.
• W4315750281 cites W3048650891 @default.
• W4315750281 cites W3092065193 @default.
• W4315750281 cites W3093228220 @default.
• W4315750281 cites W3130753680 @default.
• W4315750281 cites W3149537966 @default.
• W4315750281 cites W3173617135 @default.
• W4315750281 cites W3209145369 @default.
• W4315750281 cites W4200508346 @default.
• W4315750281 cites W4225112745 @default.
• W4315750281 cites W4285801904 @default.
• W4315750281 cites W4288041168 @default.
• W4315750281 doi "https://doi.org/10.1101/2023.01.11.23284098" @default.
• W4315750281 hasPublicationYear "2023" @default.
• W4315750281 type Work @default.
• W4315750281 citedByCount "0" @default.
• W4315750281 crossrefType "posted-content" @default.
• W4315750281 hasAuthorship W4315750281A5004380039 @default.
• W4315750281 hasAuthorship W4315750281A5004861529 @default.
• W4315750281 hasAuthorship W4315750281A5005314996 @default.
• W4315750281 hasAuthorship W4315750281A5006122583 @default.
• W4315750281 hasAuthorship W4315750281A5006651636 @default.
• W4315750281 hasAuthorship W4315750281A5007773312 @default.
• W4315750281 hasAuthorship W4315750281A5022679996 @default.
• W4315750281 hasAuthorship W4315750281A5024370074 @default.
• W4315750281 hasAuthorship W4315750281A5025856206 @default.
• W4315750281 hasAuthorship W4315750281A5032235768 @default.
• W4315750281 hasAuthorship W4315750281A5037654523 @default.
• W4315750281 hasAuthorship W4315750281A5040894984 @default.
• W4315750281 hasAuthorship W4315750281A5042241049 @default.
• W4315750281 hasAuthorship W4315750281A5042668842 @default.
• W4315750281 hasAuthorship W4315750281A5050943206 @default.
• W4315750281 hasAuthorship W4315750281A5053202977 @default.
• W4315750281 hasAuthorship W4315750281A5059475761 @default.
• W4315750281 hasAuthorship W4315750281A5059986506 @default.
• W4315750281 hasAuthorship W4315750281A5060957183 @default.
• W4315750281 hasAuthorship W4315750281A5069190300 @default.
• W4315750281 hasAuthorship W4315750281A5071524817 @default.
• W4315750281 hasAuthorship W4315750281A5075889094 @default.
• W4315750281 hasAuthorship W4315750281A5084715837 @default.
• W4315750281 hasAuthorship W4315750281A5086664284 @default.
• W4315750281 hasAuthorship W4315750281A5088680035 @default.
• W4315750281 hasBestOaLocation W43157502811 @default.
• W4315750281 hasConcept C126322002 @default.
• W4315750281 hasConcept C142724271 @default.
• W4315750281 hasConcept C168563851 @default.
• W4315750281 hasConcept C197934379 @default.
• W4315750281 hasConcept C204243189 @default.
• W4315750281 hasConcept C204787440 @default.
• W4315750281 hasConcept C207103383 @default.
• W4315750281 hasConcept C27081682 @default.
• W4315750281 hasConcept C2777910003 @default.
• W4315750281 hasConcept C2908647359 @default.
• W4315750281 hasConcept C44249647 @default.
• W4315750281 hasConcept C71924100 @default.
• W4315750281 hasConcept C90924648 @default.

• next